相关临床试验
48
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1991
进行中（未招募）
1
2.1%
已完成
18
37.5%
Enrolling By Invitation
1
2.1%
尚未招募
5
10.4%
招募中
13
27.1%
Unknown
9
18.8%
撤回
1
2.1%
暂无批准数据
- Singapore is advancing an evidence-based strategy to integrate Traditional Chinese Medicine (TCM) into its mainstream healthcare system, anchored by the Healthier SG national prevention strategy. - One in five adult Singaporeans use TCM annually, and nearly 40% of these individuals combine TCM with Western medicine for the same condition, according to MOH's 2022 National Population Health Survey. - The TCM Integrative Sandbox (TCMIS) initiative, launched in January last year, is testing evidence-based, cost-effective TCM treatments in public hospitals to generate real-world evidence. - Successful integration requires research, education and capability building, and robust governance to advance together, as outlined at the inaugural Singapore-Australia Integrative Medicine Symposium.
- Scientists at NTU Singapore developed microscopic peptide droplets that deliver siRNA to silence PD-1 and PD-L1, reducing hard-to-treat colorectal tumor growth by about 67% in mice. - The combined siRNA treatment suppressed tumor growth to a level comparable with a benchmark combination of anti-PD-1 and anti-PD-L1 antibody therapies. - The approach targets microsatellite-stable (MSS) colorectal cancer, which accounts for about 85% of cases and responds poorly to existing checkpoint inhibitors. - Researchers estimate the siRNA-based platform could cost five to 10 times less to manufacture than monoclonal antibody immunotherapies if successfully scaled up.
- An international team led by NTU Singapore has identified faecal Angptl4 as a potential stool biomarker for gut barrier dysfunction, an early contributor to metabolic dysfunction-associated steatotic liver disease (MASLD). - The study, published in Nature Communications, used mouse models and clinical data from three Asian patient cohorts in Thailand, China, and India to validate the findings across diverse populations. - Researchers found that faecal Angptl4 levels rise alongside gut microbial imbalance and metabolic dysfunction, offering a simpler, non-invasive monitoring method compared to blood markers. - The team is working to streamline the PCR-based test for routine clinical use and exploring integration with existing stool-based screening programs like Singapore's Healthier SG.
- Researchers from NIE NTU Singapore, SMART, MIT, NUH, and NUS Medicine developed the first optical nanosensor specifically designed to detect indole-3-propionic acid (IPA), a key gut health biomarker. - The dual-mode platform operates in visible fluorescence for rapid screening and near-infrared for potential in vivo and wearable applications, delivering results within minutes. - Validated in 125 human plasma samples, the sensor revealed significantly lower IPA levels in patients with active inflammatory bowel disease, including Crohn's disease and ulcerative colitis. - The team has been awarded an Innovation to Startup (I2Start) grant to incubate a proto-startup aimed at translating the sensor into a point-of-care clinical diagnostic tool.
- LKCMedicine held its annual convocation on 25 August 2026, conferring MBBS degrees to 169 graduates at the Novena campus. - Dr Janil Puthucheary, Senior Minister of State, delivered the keynote address emphasizing lifelong learning as a professional responsibility for physicians. - Dr Loh Pei Yi received multiple top honors including the NTU President's Prize for Community Service and the Lee Kuan Yew Gold Medal. - Graduates reflected on transformative experiences including overseas electives in Uganda and the UK, community service in India, and balancing elite athletics with medical training.
- Singapore will conduct a clinical study involving 1,000 high-risk participants in the second half of 2026 to evaluate multi-cancer early detection (MCED) tests, which use liquid biopsies to screen for multiple cancers in a single blood test. - The study addresses the lack of evidence for MCED test performance in Asian populations, as most existing trials were conducted in predominantly Caucasian populations with different cancer epidemiology and genetic architecture. - A second study called CRAnE will focus on targeted screening for cancers linked to metabolic dysfunctions such as diabetes, obesity, and high cholesterol in primary care settings. - Both studies are launched by the newly established Research Institute for Cancer Prevention, Screening and Early Detection (RISE), jointly led by National Cancer Centre Singapore and Nanyang Technological University's medical school.
- Researchers from NUS Medicine have developed a dual RNA-based therapy that effectively targets KRAS mutations, found in over 90% of pancreatic cancers and long considered "undruggable." - The combination treatment uses antisense oligonucleotides to silence mutant KRAS genes and immunomodulatory RNA to activate immune responses, delivered via red blood cell-derived extracellular vesicles. - Preclinical studies showed the therapy converted "cold" tumors into "hot" ones recognizable by the immune system, markedly suppressing tumor growth and extending survival without observable toxicity. - The platform shows particular promise for pancreatic ductal adenocarcinoma with peritoneal metastasis, addressing a major unmet medical need in one of cancer's deadliest forms.
- Nanyang Biologics has partnered with Equinix, Hewlett Packard Enterprise, and Nvidia to develop Vecura, an AI-enabled drug discovery platform that can identify potential drug candidates in as little as six minutes by 2026. - The platform builds on the company's earlier DTIGN technology, which successfully identified 15 potential drug candidates within six months for a Japanese pharmaceutical firm using graph neural networks and a library of compounds from over 50,000 organisms. - The global drug discovery platform market is projected to grow from $186 million in 2024 to $635 million by 2034, representing a compound annual growth rate of over 13 percent. - This collaboration positions Singapore as a leading hub for AI-enabled drug discovery, with Nanyang Biologics planning to commercialize the platform for other pharmaceutical companies while retaining intellectual property ownership.
- Researchers from NTU and MIT developed COMET, an AI model that predicts optimal lipid nanoparticle formulations for RNA medicine delivery, published in Nature Nanotechnology. - The transformer-based neural network can identify the best nanoparticle designs among millions of possibilities without extensive laboratory testing, reducing development timelines from months to weeks. - COMET-designed lipid nanoparticles outperformed clinically approved benchmarks in both laboratory and animal studies, demonstrating superior delivery performance. - The technology extends beyond pandemic preparedness to enable RNA therapies targeting specific organs and cell types for treating cancers and metabolic disorders.
- Singapore's National Centre for Infectious Diseases has conducted the country's first COVID-19 human challenge study, deliberately exposing five vaccinated volunteers to the virus under controlled conditions. - The Sing-CoV trial aims to recruit 20 healthy participants aged 21-30 by October 2024, with researchers collecting comprehensive biological samples to gain precise insights into infection dynamics despite vaccination. - This pioneering study establishes a framework for future challenge trials, including the upcoming global MUSICC study in 2025, strengthening Singapore's preparedness for future pandemics including potential "Disease X" threats.
